NCT03907722 is a clinical trial of Long pentraxin 3 in STEMI, sponsored by Indonesian Cardiovascular Research Center.

Who is sponsoring NCT03907722?

NCT03907722 is sponsored by Indonesian Cardiovascular Research Center.

What drugs are being tested in NCT03907722?

Interventions in NCT03907722: Long pentraxin 3.

What condition does NCT03907722 study?

NCT03907722 studies STEMI, Microvascular Coronary Artery Disease.

Is NCT03907722 still recruiting?

NCT03907722 is currently completed. Last updated 11 April 2019.

Last reviewed 2019-04-11 · How we verify

NCT03907722

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The 3q25 rs2305619 Polymorphism Associates With Microvascular Obstruction in STEMI

Completed Last updated 11 April 2019

What this trial tests

trial testing Long pentraxin 3 in STEMI in 217 participants. Completed in 3 September 2018.

Timeline

1 January 2018

Primary endpoint
2 August 2018

3 September 2018

Quick facts

Lead sponsor	Indonesian Cardiovascular Research Center
Status	Completed
Study type	OBSERVATIONAL
Enrollment	217
Start date	1 January 2018
Primary completion	2 August 2018
Estimated completion	3 September 2018
Sites	1 location across Indonesia

Drugs / interventions tested

Long pentraxin 3

Conditions studied

STEMI — all drugs for STEMI →
Microvascular Coronary Artery Disease — all drugs for Microvascular Coronary Artery Disease →

Sponsor

Indonesian Cardiovascular Research Center

Who can join

Eligibility, any sex, with STEMI or Microvascular Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators enrolled 217 patients with acute STEMI undergoing primary PCI. The rs2305619 polymorphism was evaluated by real time PCR and plasma PTX3 concentration was assessed by human PTX3 ELISA kit.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for STEMI

Currently open trials in the same condition.

NCT06966674 — No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track · NA · recruiting
NCT06678074 — Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI · Phase 1, PHASE2 · active not recruiting
NCT07055152 — Retinal OCTA for Microvascular Dysfunction Evaluation and Outcome Prediction in MINOCA Patients · recruiting
NCT06528821 — AI-Powered ECG Detecting Culprit Vessel Blood Flow Abnormality in ACS · active not recruiting
NCT07026708 — TIRANA-ACS: A Prospective Registry Study for the Targeted Investigation of Residual Inflammation After Non-ST/ ST Elevat · recruiting

Other Indonesian Cardiovascular Research Center trials

Trials by the same sponsor.

NCT03894176 — Association of Plasma PTX3 Concentration and Outcomes of STEMI · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03907722 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Indonesian Cardiovascular Research Center
Last refreshed: 11 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03907722.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing